Gamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. Its lead product, NiCord®, offers patients in need of HSCT an alternative to the existing approach of bone marrow transplant by using ex vivo expansion of cord blood. In clinical trials so far, NiCord® has demonstrated rapid engraftment and clinical outcomes that appear comparable to transplantation of peripheral blood. [Read more…]
Stemedica Begins Clinical Trials in U.S. Using Human Allogeneic Mesenchymal Stem Cells (MSCs) to Treat Alzheimer’s Disease
In major news released today, Stemedica announced that it is beginning clinical trials in the Unites States using allogeneic human mesenchymal stem cells (MSCs) to treat Alzheimer’s Disease. This Phase IIa clinical study is a major advance toward the use of cell-based solutions to address degenerative brain conditions.
Stemedica International S.A. is a subsidiary of Stemedica Cell Technologies, Inc., a global biotechnology company that manufactures adult allogeneic stem cells.
RoosterBio and US Army Partner to Develop Stem Cell-Based Therapies for Wounded Warriors
RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation. In today’s announcement, RoosterBio announced that it has entered into a Cooperative Research and Development Agreement (CRADA) that will enable “collaborative development of innovative stem cell-based therapies related to wounded warrior injuries and rehabilitation.” [Read more…]
WideCells Group PLC, a Global Stem Cell Services Company, Goes Public with £2m IPO
WideCells Group PLC (‘WideCells Group’ or ‘the Group’) £2m Placing, Admission to Trading and First Day of Dealings
WideCells Group; 27 July 2016 — WideCells Group, the health care services company focused on collecting and storing stem cells and providing ground breaking insurance for stem cell treatment, is pleased to announce that the entire issued share capital of 54,058,061 ordinary shares of 0.25p each (‘Ordinary Shares’) will today be admitted to the Standard Listing segment of the Official List of the UK Listing Authority and to trading on the Main Market for listed securities of the London Stock Exchange (together ‘Admission’). The Company will be trading under the ticker symbol WDC with the ISIN number GB00BD060S65. [Read more…]
Introduction to Cord Tissue-Derived Mesenchymal Stem Cells (CT-MSCs)
The past few years have seen major change within the global cord blood banking industry, with new trends emerging, shifts in public perception toward cord blood storage, improving techniques for the use of cord blood in cellular therapy, and more.
The post below discusses important trends in umbilical cord tissue storage and the degree to which these trends are impacting cord blood market participants.
How the Cord Tissue Banking Market Began
The storage of umbilical cord tissue has been a significant trend within the cord blood industry over the past few years. The reason to store both umbilical cord blood and tissue is that they contain different types of stem cells, each with the potential to treat different types of injury or disease. In cord tissue banking, 4-8 cm of the umbilical cord is collected, placed in the tissue collection kit, and transported to a cord blood bank for processing and storage. [Read more…]
- « Previous Page
- 1
- …
- 152
- 153
- 154
- 155
- 156
- …
- 201
- Next Page »